Σύγκριση μεθόδων

	Διαγνωστικά Κριτήρια Rome IV για το Σύνδρομο Ευερέθιστου Εντέρου	Κλίμακα Ποιότητας Ζωής Σχετιζόμενης με την Υγεία λόγω ΓΟΠ	Δείκτης Απλού Κλινικού Ενεργότητας Κολίτιδας
Πεδίο	Γαστρεντερολογία	Γαστρεντερολογία	Γαστρεντερολογία
Οικογένεια	Process / pipeline	Process / pipeline	Process / pipeline
Έτος προέλευσης	2016	1996	1998
Δημιουργός	Rome Foundation (multinational expert consensus)	Velanovich, V., Zhang, Y., Hollis, J. B., et al.	Walmsley, R. S., Ayres, R. C., Pounder, R. E., and Allan, R. N.
Τύπος	Diagnostic Criteria	Self-report	Clinician-rated
Θεμελιώδης πηγή	Mearin, F., Lacy, B. E., Chang, L., et al. (2016). Bowel disorders. Gastroenterology. Published online June 2016 by the Rome Foundation.	Velanovich, V., Zhang, Y., Hollis, J. B., Feldman, M. I., Sampliner, R., Guan, W., & Escamilla, C. (1996). Presenting symptoms and outcome measures in reflux esophagitis. Digestive Diseases and Sciences, 41(10), 1865–1873.	Walmsley, R. S., Ayres, R. C., Pounder, R. E., & Allan, R. N. (1998). A simple clinical colitis activity index. Gut, 43(1), 29–32.
Εναλλακτικές ονομασίες	Rome IV IBS, Rome Criteria	GERD-HRQL, GERD-HRQoL	SCCAI
Συναφείς	4	4	4
Σύνοψη	The Rome IV criteria are the internationally accepted diagnostic standard for irritable bowel syndrome (IBS), published in 2016 by the Rome Foundation. These criteria define IBS as recurrent abdominal pain (≥1 day per week for ≥3 months) associated with altered bowel habits, without structural or biochemical abnormalities. IBS is subtyped into four patterns—IBS-constipation predominant (IBS-C), IBS-diarrhea predominant (IBS-D), IBS-mixed (IBS-M), and IBS-unclassified (IBS-U)—based on stool consistency patterns.	The GERD Health-Related Quality of Life Scale (GERD-HRQL) is a concise, validated patient-reported outcome measure for assessing the symptomatic and functional impact of gastroesophageal reflux disease (GERD). Developed by Velanovich and colleagues in 1996, the 9-item GERD-HRQL measures heartburn frequency and severity, regurgitation, and impact on sleep and medication use. The scale is highly responsive to proton pump inhibitor (PPI) therapy and is widely used in GERD trials and clinical practice.	The Simple Clinical Colitis Activity Index (SCCAI) is a practical, bedside tool for assessing disease activity in ulcerative colitis and colonic Crohn's disease. Published in 1998 by Walmsley and colleagues, the SCCAI condenses disease assessment into six items that can be administered in a office visit without laboratory or endoscopic data. It provides rapid, reproducible quantification of disease severity and is ideal for frequent monitoring in routine clinical practice.